BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

Pfizer’s Rituxan biosimilar approved in U.S. FDA approved Ruxience rituximab-pvvr from Pfizer Inc. (NYSE:PFE) for non-Hodgkin lymphoma, chronic lymphocytic leukemia and granulomatosis with polyangitis and microscopic polyangitis. Ruxience is the second biosimilar of Rituxan, an...
BioCentury | Feb 8, 2019
Company News

Sanofi seeking partner to develop Oxford BioMedica's ophthalmology gene therapies

Oxford BioMedica plc (LSE:OXB) said Sanofi (Euronext:SAN; NASDAQ:SNY) will seek a partner to continue further development of two ophthalmology gene therapy programs that the pharma gained under a 2009 deal with Oxford BioMedica. The products...
BioCentury | Sep 14, 2018
Product R&D

Academia’s manufacturing problem

With backups at academic manufacturing centers beginning to hamper translation of early stage gene therapies, pushing those who can afford it to CMOs, at least one non-profit has stepped in with a model to deliver...
BioCentury | Aug 10, 2018
Finance

Sound story

Preclinical data supporting Akouos Inc.’s hearing loss program convinced 5AM Ventures to re-up for a $50 million series A round, and those funds plus additions to the Akouos team have the company poised to take...
BioCentury | Aug 10, 2018
Financial News

Hearing loss play Akouos grabs $50M series A

Akouos Inc. (Boston, Mass.) raised $50 million on Aug. 7 in a series A round co-led by existing investors 5AM Ventures and New Enterprise Associates. Partners Innovation Fund and new investors Sofinnova Ventures, RA Capital...
BioCentury | Aug 7, 2018
Financial News

Hearing loss play Akouos grabs $50M series A

Akouos Inc. (Boston, Mass.) raised $50 million in a series A round co-led by existing investors 5AM Ventures and New Enterprise Associates. Partners Innovation Fund and new investors Sofinnova Ventures, RA Capital Management and Novartis...
BioCentury | Dec 8, 2017
Company News

Akouos licenses gene therapy tech from Massachusetts Eye and Ear

Newco Akouos Inc. (Boston, Mass.) acquired an exclusive license to a vector platform from Massachusetts Eye and Ear (Boston, Mass.) and Lonza Group Ltd. (SIX:LONN) to develop gene therapies for hearing and balance disorders. The...
BioCentury | Dec 1, 2017
Company News

Akouos in-licenses gene therapy vectors from Mass. Eye and Ear

Newco Akouos Inc. (Boston, Mass.) acquired an exclusive license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear (Boston, Mass.) and Lonza Group Ltd. (SIX:LONN). The...
BioCentury | Oct 4, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2017

New Therapeutic Targets and Biomarkers: September 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during September 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Sep 14, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

...Calcium and integrin binding family member 2 (CIB2; USH1J) Patient sample, cell culture and mouse studies suggest promoting the expression of CIB2...
Items per page:
1 - 10 of 49